NCT01261130View on ClinicalTrials.gov

Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

August 31, 2014

Study Completion Date

December 31, 2014

Conditions
Hookworm InfectionHookworm Disease
Interventions
BIOLOGICAL

10 μg Na-GST-1/Alhydrogel

3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals

BIOLOGICAL

30 μg Na-GST-1/Alhydrogel

3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals

BIOLOGICAL

100 μg Na-GST-1/Alhydrogel

3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals

BIOLOGICAL

10 μg Na-GST-1/ Alhydrogel/GLA-AF

3 doses 10 μg Na-GST-1/ Alhydrogel/GLA-AF administered at 56 day intervals

BIOLOGICAL

30 μg Na-GST-1/Alhydrogel/GLA-AF

3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals

BIOLOGICAL

100 μg Na-GST-1/Alhydrogel/GLA-AF

3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals

BIOLOGICAL

Butang® hepatitis B vaccine

3 doses Butang® hepatitis B vaccine administered at 56 day intervals

Trial Locations (2)

Unknown

Americaninhas Vaccine Center, Americaninha

Centro de Pesquisas René Rachou - FIOCRUZ, Belo Horizonte

All Listed Sponsors
lead

Baylor College of Medicine

OTHER

NCT01261130 - Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults | Biotech Hunter | Biotech Hunter